Inoviq Ltd Cash Flow Conversion Efficiency
Inoviq Ltd cash flow conversion efficiency. Based on the latest financial reports, Inoviq Ltd (IIQ) has a cash flow conversion efficiency ratio of -0.098x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.18 Million ≈ $-1.54 Million USD) by net assets (AU$22.26 Million ≈ $15.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Inoviq Ltd (1991–2025)
Cash flow conversion efficiency of Inoviq Ltd from 1991 to 2025. This chart illustrates how Inoviq Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Inoviq Ltd stock quote for real-time trading data and today's change.
Inoviq Ltd Cash Flow Conversion Ratio Explained
Inoviq Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Inoviq Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inoviq Ltd ranked by their cash flow conversion efficiency. Also see Inoviq Ltd market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bionano Genomics Inc
NASDAQ:BNGO
|
-0.148x |
|
Riversgold Ltd
AU:RGL
|
-19.655x |
|
Managepay Systems Bhd
KLSE:0156
|
-0.012x |
|
Tellusgruppen AB
ST:TELLUS
|
0.738x |
|
Thunderful Group AB
ST:THUNDR
|
-0.023x |
|
ASTORY Co.Ltd
KQ:241840
|
-0.064x |
|
Mida Leasing Public Company Limited
BK:ML
|
0.018x |
|
Glen Burnie Bancorp
NASDAQ:GLBZ
|
0.020x |
Annual Cash Flow Conversion Efficiency for Inoviq Ltd (1991–2025)
The table below shows the annual cash flow conversion efficiency of Inoviq Ltd from 1991 to 2025. Review how much free cash does Inoviq Ltd generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$16.71 Million ≈ $11.83 Million |
AU$-4.66 Million ≈ $-3.30 Million |
-0.279x | -28.97% |
| 2024-06-30 | AU$19.99 Million ≈ $14.14 Million |
AU$-4.32 Million ≈ $-3.06 Million |
-0.216x | +39.60% |
| 2023-06-30 | AU$19.62 Million ≈ $13.88 Million |
AU$-7.02 Million ≈ $-4.97 Million |
-0.358x | -67.16% |
| 2022-06-30 | AU$28.29 Million ≈ $20.02 Million |
AU$-6.06 Million ≈ $-4.29 Million |
-0.214x | -18.33% |
| 2021-06-30 | AU$29.06 Million ≈ $20.56 Million |
AU$-5.26 Million ≈ $-3.72 Million |
-0.181x | +53.79% |
| 2020-06-30 | AU$6.48 Million ≈ $4.58 Million |
AU$-2.54 Million ≈ $-1.79 Million |
-0.392x | -77.94% |
| 2019-06-30 | AU$7.13 Million ≈ $5.05 Million |
AU$-1.57 Million ≈ $-1.11 Million |
-0.220x | +87.34% |
| 2018-06-30 | AU$1.13 Million ≈ $799.89K |
AU$-1.97 Million ≈ $-1.39 Million |
-1.738x | +81.15% |
| 2017-06-30 | AU$257.94K ≈ $182.51K |
AU$-2.38 Million ≈ $-1.68 Million |
-9.221x | -33350.54% |
| 2016-06-30 | AU$2.83 Million ≈ $2.01 Million |
AU$-78.12K ≈ $-55.27K |
-0.028x | +61.75% |
| 2015-06-30 | AU$1.76 Million ≈ $1.24 Million |
AU$-126.65K ≈ $-89.62K |
-0.072x | -164.40% |
| 2014-06-30 | AU$888.13K ≈ $628.41K |
AU$99.38K ≈ $70.31K |
0.112x | +142.47% |
| 2013-06-30 | AU$2.92 Million ≈ $2.06 Million |
AU$-768.54K ≈ $-543.79K |
-0.263x | -465.92% |
| 2012-06-30 | AU$15.11 Million ≈ $10.69 Million |
AU$-703.24K ≈ $-497.59K |
-0.047x | +19.70% |
| 2011-06-30 | AU$26.60 Million ≈ $18.82 Million |
AU$-1.54 Million ≈ $-1.09 Million |
-0.058x | -42.54% |
| 2010-06-30 | AU$18.89 Million ≈ $13.37 Million |
AU$-768.35K ≈ $-543.66K |
-0.041x | +4.20% |
| 2009-06-30 | AU$19.03 Million ≈ $13.46 Million |
AU$-807.86K ≈ $-571.61K |
-0.042x | +65.11% |
| 2008-06-30 | AU$5.67 Million ≈ $4.01 Million |
AU$-689.60K ≈ $-487.93K |
-0.122x | +93.15% |
| 2007-06-30 | AU$2.04 Million ≈ $1.45 Million |
AU$-3.63 Million ≈ $-2.57 Million |
-1.777x | -264.88% |
| 2006-06-30 | AU$11.04 Million ≈ $7.81 Million |
AU$-5.38 Million ≈ $-3.80 Million |
-0.487x | -75.52% |
| 2005-06-30 | AU$16.88 Million ≈ $11.95 Million |
AU$-4.68 Million ≈ $-3.31 Million |
-0.277x | +19.00% |
| 2004-06-30 | AU$2.78 Million ≈ $1.97 Million |
AU$-952.64K ≈ $-674.05K |
-0.342x | +39.62% |
| 2003-06-30 | AU$2.48 Million ≈ $1.76 Million |
AU$-1.41 Million ≈ $-996.59K |
-0.567x | -127.34% |
| 2002-06-30 | AU$2.33 Million ≈ $1.65 Million |
AU$-580.86K ≈ $-411.00K |
-0.249x | -177.20% |
| 1999-06-30 | AU$9.09 Million ≈ $6.43 Million |
AU$-818.36K ≈ $-579.04K |
-0.090x | +0.39% |
| 1997-06-30 | AU$10.44 Million ≈ $7.39 Million |
AU$-943.60K ≈ $-667.65K |
-0.090x | -57.33% |
| 1996-06-30 | AU$10.31 Million ≈ $7.29 Million |
AU$-591.98K ≈ $-418.86K |
-0.057x | +6.84% |
| 1995-06-30 | AU$9.89 Million ≈ $7.00 Million |
AU$-610.00K ≈ $-431.61K |
-0.062x | +60.69% |
| 1994-06-30 | AU$9.72 Million ≈ $6.88 Million |
AU$-1.52 Million ≈ $-1.08 Million |
-0.157x | +82.55% |
| 1993-06-30 | AU$1.61 Million ≈ $1.14 Million |
AU$-1.45 Million ≈ $-1.02 Million |
-0.899x | +62.96% |
| 1992-06-30 | AU$286.00K ≈ $202.36K |
AU$-694.00K ≈ $-491.05K |
-2.427x | -128.19% |
| 1991-06-30 | AU$-23.00K ≈ $-16.27K |
AU$-198.00K ≈ $-140.10K |
8.609x | -- |
About Inoviq Ltd
INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non… Read more